Idorsia (SWX:IDIA) Unveils Fresh Clinical Data, Is It Still 21% Below Fair Value?
Idorsia (SWX:IDIA) has put fresh clinical data for its two key drugs in front of specialist audiences, with new findings on daridorexant and aprocitentan presented at major congresses in October 2026.
Against that backdrop, Idorsia’s 1-day share price return of 3.65% suggests the fresh clinical data caught investor attention, although the 30-day share price return is down 16.04% and the 90-day share price return is down 30.95%. Meanwhile, the 3-year total shareholder return of about 2x hints that sentiment has already swung sharply over a longer horizon.
Scan how Idorsia’s clinical momentum compares with peers by reviewing a curated set of 127 healthcare AI stocks that are focused on advances in data-driven therapies and next-generation treatment platforms.
Idorsia now trades well below recent highs despite the clinical spotlight it just received. Is most of the rerating already done, or does the current valuation still leave meaningful upside on the table?
Most Popular Narrative: 21% Undervalued
Idorsia closed at about CHF4.20, while the most followed narrative pegs fair value closer to CHF5.33. The current quote prices in a clear discount that hinges on how its drugs and partnerships convert into future earnings.
Approval and launch readiness of TRYVIO (aprocitentan) in resistant hypertension, with broadened label and key differentiation in high-need populations (e.g., chronic kidney disease), positions Idorsia to capitalize on a >$12 billion market with strong payer and prescriber receptivity, potentially boosting future revenue and cash flow.
See why 8 investors see Idorsia as 21% undervalued.
Result: Fair Value of CHF5.33 (UNDERVALUED)
Still, Idorsia’s story could shift quickly if QUVIVIQ gains faster reimbursement access or if TRYVIO uptake in resistant hypertension tracks the more optimistic analyst scenarios.
Find out about the key risks to this Idorsia narrative.
Next Steps
Mixed signals in the Idorsia story can either sharpen conviction or sow doubt, so move quickly, review the underlying data, and weigh both the upside and the concerns by focusing on 3 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Idorsia?
If Idorsia has sharpened your focus, do not stop here. Broaden your watchlist with ideas that balance potential, quality, and risk in different ways.
- Target potential value gaps by reviewing companies that screen as 178 high quality undervalued stocks based on solid fundamentals and pricing that still looks compressed.
- Prioritise resilience in uncertain conditions by scanning a list of solid balance sheet and fundamentals (204 results) that can better handle shocks without constant refinancing worries.
- Get ahead of the crowd by spotting 618 high quality undiscovered gems before they attract broad market attention and tighter pricing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com